Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Q1 2017 · 10-Q
Revenue—
Net Income$3.28M$3.28MN/M vs Q1 2016 EPS Diluted-$2.33-$2.33N/M vs Q1 2016 Operating Income$3,498,886N/M Operating Cash Flow-$4,037,296N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
Free Cash Flowderived-$4,040,568N/M ended Mar 31, 2017 · filed May 10, 2017 · 40 d after period end